Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

ENETS 2016 Munich Advisory Board Participants

doi:10.1159/000493319

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

ENETS 2016 Munich Advisory Board Participants

Department of Clinical Medicine

6 Citations (Scopus)

Abstract

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Original language	English
Journal	Neuroendocrinology
Volume	108
Issue number	1
Pages (from-to)	18-25
ISSN	0028-3835
DOIs	https://doi.org/10.1159/000493319
Publication status	Published - 1 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000493319

Cite this

@article{215dc51feffa4d07987f46032927cae8,

title = "Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms",

abstract = "Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.",

author = "Jaume Capdevila and Lisa Bodei and Philippa Davies and Vera Gorbounova and Jensen, {Robert T} and Knigge, {Ulrich P} and Krejs, {Guenter J} and Eric Krenning and O'Connor, {Juan Manuel} and Marc Peeters and Guido Rindi and Ramon Salazar and Marie-Pierre Vullierme and Pavel, {Marianne E} and ENETS 2016 Munich Advisory Board Participants",

note = "{\textcopyright}2018 S. Karger AG, Basel.",

year = "2019",

month = jan,

day = "1",

doi = "10.1159/000493319",

language = "English",

volume = "108",

pages = "18--25",

journal = "Neuroendocrinology",

issn = "0028-3835",

publisher = "S Karger AG",

number = "1",

}

TY - JOUR

T1 - Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

AU - Capdevila, Jaume

AU - Bodei, Lisa

AU - Davies, Philippa

AU - Gorbounova, Vera

AU - Jensen, Robert T

AU - Knigge, Ulrich P

AU - Krejs, Guenter J

AU - Krenning, Eric

AU - O'Connor, Juan Manuel

AU - Peeters, Marc

AU - Rindi, Guido

AU - Salazar, Ramon

AU - Vullierme, Marie-Pierre

AU - Pavel, Marianne E

AU - ENETS 2016 Munich Advisory Board Participants

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

AB - Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

U2 - 10.1159/000493319

DO - 10.1159/000493319

M3 - Comment/debate

C2 - 30153686

SN - 0028-3835

VL - 108

SP - 18

EP - 25

JO - Neuroendocrinology

JF - Neuroendocrinology

IS - 1

ER -

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this